Clinical Trials
13 trialsNCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00112242 2020-06-18
Immunotherapy of Stage III/IV Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT02320305 2020-01-14
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT01748747 2018-10-09
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00074230 2015-05-12
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
University Hospital Erlangen
Phase 1/2 Completed
NCT00005841 2014-05-22
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 1 Terminated
NCT00006113 2014-05-22
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 2 Terminated
NCT00025181 2014-05-22
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
University of Southern California
Phase 1 Completed
NCT00031733 2014-05-22
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Phase 2 Completed
NCT00334776 2014-05-21
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Southern California
Phase 2 Completed
NCT00002952 2013-09-05
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
University of Chicago
Phase 1/2 Completed
NCT00559026 2007-11-16
DTIC-melvacc
Istituto Superiore di SanitÃ
Phase 1 Completed